Mangala Rajan

Mangala Rajan

Auto-generated profile, based on publicly available information

Mangala Rajan

Department of Medicine, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Public Health
Verified
Journal Article
Closed access
AGArnab Ghosh
Arnab Ghosh
SVS. Venkatraman
S. Venkatraman
OSO. Soroka
O. Soroka
ERE. Reshetnyak
E. Reshetnyak
MRM. Rajan
M. Rajan
NHN. Hupert
N. Hupert

17 November 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
PGParag Goyal
Parag Goyal
JRJoanna Bryan Ringel
Joanna Bryan Ringel
MRMangala Rajan
Mangala Rajan
JCJustin J. Choi
Justin J. Choi
LPLaura C. Pinheiro
Laura C. Pinheiro
MSMonika M. Safford
Monika M. Safford

2 September 2021 in BMC Medical Education
Verified
Journal Article
Open access
PDF file
JTJudy Tung
Judy Tung
MNMusarrat Nahid
Musarrat Nahid
MRMangala Rajan
Mangala Rajan
LLLia Logio
Lia Logio
Background: Academic medical centers invest considerably in faculty development efforts to support the career success and promotion of their faculty, and to minimize faculty attrition. This study evaluated the impact of a faculty development program called the Leadership in Academic Medicine Program (LAMP) on participants’ (1) self-ratings of efficacy, (2) promotion in academic rank, and (3) institutional retention. Method: Participants from the 2013–2020 LAMP cohorts were surveyed pre and post program to assess their level of agreement with statements that spanned domains of self-awareness, self-efficacy, satisfaction with work and work environment. Pre and post responses were compared using McNemar’s tests. Changes in scores across gender were compared using Wilcoxon Rank Sum/Mann-Whitney tests. LAMP participants were matched to nonparticipant controls by gender, rank, department, and time of hire to compare promotions in academic rank and departures from the organization. Kaplan Meier curves and Cox proportional hazards models were used to examine differences. Results: There were significant improvements in almost all self-ratings on program surveys (p < 0.05). Greatest improvements were seen in “understand the promotions process” (36% vs. 94%), “comfortable negotiating” (35% vs. 74%), and “time management” (55% vs. 92%). There were no statistically significant differences in improvements by gender, however women faculty rated themselves lower on all pre-program items compared to men. There was significant difference found in time-to-next promotion (p = 0.003) between LAMP participants and controls. Kaplan-Meier analysis demonstrated that LAMP faculty achieved next promotion more often and faster than controls. Cox-proportional-hazards analyses found that LAMP faculty were 61% more likely to be promoted than controls (hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.16–2.23, p-value = 0.004). There was significant difference found in time-to-departure (p < 0.0001) with LAMP faculty retained more often and for longer periods. LAMP faculty were 77% less likely to leave compared to controls (HR 0.23, 95% CI 0.16–0.34, p < 0.0001). Conclusions: LAMP is an effective faculty development program as measured subjectively by participant self-ratings and objectively through comparative improvements in academic promotions and institutional retention.

1 September 2021 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
SLSarah B. Lieber
Sarah B. Lieber
MNMusarrat Nahid
Musarrat Nahid
SPStephen Paget
Stephen Paget
JBJessica R. Berman
Jessica R. Berman
MBMedha Barbhaiya
Medha Barbhaiya
LMLisa A. Mandl
Lisa A. Mandl
Objective: Frailty is associated with mortality in systemic lupus erythematosus (SLE), but how best to measure frailty is unclear. We aimed to compare 2 frailty metrics, the self-reported Fatigue, Resistance, Ambulation, Illnesses, and Loss of weight (FRAIL) scale (FS) and the Fried phenotype (FP), in SLE to evaluate differences between frail and nonfrail women and whether frailty is associated with self-reported disability.Methods: Adult women aged < 70 years with validated SLE and mild/moderate disease enrolled in this cross-sectional study between August 2018 and October 2019. Correlation and agreement between the FS and the FP were determined. Differences in sociodemographic and disease characteristics, patient-reported outcome measures (PROMs), and biomarkers between frail and nonfrail participants were evaluated, as well as the association of frailty with Valued Life Activities disability.Results: Of 67 participants, 27% and 18% were frail according to the FS and the FP, respectively. Correlation (r= 0.51;P< 0.0001) and agreement (κ = 0.46;P= 0.0004) between the FS and the FP were significant. Frail women had greater disease damage, high-sensitivity C-reactive protein, and interleukin 6, and worse PROMs according to both frailty definitions. Both frailty measures were associated with self-reported disability after adjustment for age, comorbidity, and disease activity and damage; this relationship was attenuated for the FP.Conclusion: Frailty prevalence was high in this cohort of women with SLE using both frailty definitions, suggesting that frailty may be accelerated in women with SLE, particularly when based exclusively on self-report. Frailty remained associated with self-reported disability in adjusted analyses. The FS may be an informative point-of-care tool to identify frail women with SLE.

26 March 2021 in medRxiv
Verified
Preprint
Open access
PDF file
MRMoritz Reiterer
Moritz Reiterer
MRMangala Rajan
Mangala Rajan
NGNicolás Gómez-Banoy
Nicolás Gómez-Banoy
JLJennifer D. Lau
Jennifer D. Lau
LGLuis G. Gomez-Escobar
Luis G. Gomez-Escobar
JLJames C. Lo
James C. Lo
COVID-19 has proven to be a metabolic disease resulting in adverse outcomes in individuals with diabetes or obesity. Patients infected with SARS-CoV-2 and hyperglycemia suffer from longer hospital stays, higher risk of developing acute respiratory distress syndrome (ARDS), and increased mortality compared to those who do not develop hyperglycemia. Nevertheless, the pathophysiological mechanism(s) of hyperglycemia in COVID-19 remains poorly characterized. Here we show that insulin resistance rather than pancreatic beta cell failure is the prevalent cause of hyperglycemia in COVID-19 patients with ARDS, independent of glucocorticoid treatment. A screen of protein hormones that regulate glucose homeostasis reveals that the insulin sensitizing adipokine adiponectin is reduced in hyperglycemic COVID-19 patients. Hamsters infected with SARS-CoV-2 also have diminished expression of adiponectin. Together these data suggest that adipose tissue dysfunction may be a driver of insulin resistance and adverse outcomes in acute COVID-19.

19 April 2023 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
OFOlivia Fankuchen
Olivia Fankuchen
JLJennifer Lau
Jennifer Lau
MRMangala Mba Rajan
Mangala Mba Rajan
BSBrandon Swed
Brandon Swed
PMPeter Martin
Peter Martin
MSManish A Shah
Manish A Shah
Objectives: The long-term effects of severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019 [COVID-19]) infection in patients with cancer are unknown. We examined 1-year mortality and prevalence of long COVID in patients with and without cancer after initial hospitalization for acute COVID-19 infection. Methods: We previously studied 585 patients hospitalized from March to May 2020 with acute COVID-19 infection at Weill Cornell Medicine (117 patients with cancer and 468 age, sex, and comorbidity-matched non-cancer controls). Of the 456 patients who were discharged, we followed 359 patients (75 cancer and 284 non-cancer controls) for COVID-related symptoms and death, at 3, 6, and 12 months after initial symptom onset. Pearson χ2 and Fisher exact tests were used to determine associations between cancer, postdischarge mortality, and long COVID symptoms. Multivariable Cox proportional hazards models adjusting for potential confounders were used to quantify the risk of death between patients with and without cancer. Results: The cancer cohort had higher mortality after hospitalization (23% vs 5%, P < 0.001), a hazard ratio of 4.7 (95% CI: 2.34-9.46) for all-cause mortality, after adjusting for smoking and oxygen requirement. Long COVID symptoms were observed in 33% of patients regardless of cancer status. Constitutional, respiratory, and cardiac complaints were the most prevalent symptoms in the first 6 months, whereas respiratory and neurological complaints (eg, “brain fog” and memory deficits) were most prevalent at 12 months. Conclusions: Patients with cancer have higher mortality after hospitalization for acute severe acute respiratory syndrome coronavirus 2 infections. The risk of death was highest in the first 3 months after discharge. About one-third of all patients experienced long COVID.